Extended RESONATE Data Illuminates Ibrutinib's Benefits in High-Risk CLLMay 16th 2016
Extended follow-up data continue to demonstrate the efficacy and tolerability of ibrutinib in previously treated patients with chronic lymphocytic leukemia, including those with high-risk gene mutations and prognostic features.
Entrectinib Shows Dramatic Response in Rare Salivary Gland TumorMay 9th 2016
The experimental targeted therapy entrectinib demonstrated a dramatic response in a patient with metastatic mammary analog secretory carcinoma (MASC), which is<br /> a rare form of salivary gland cancer.
Frontline Myeloma Therapies Undergoing Dramatic TransformationMay 5th 2016
The high level of efficacy observed with the combination of bortezomib, lenalidomide, and dexamethasone in the phase III SWOG S0777 study significantly changed the frontline treatment paradigm for patients with multiple myeloma.
Shortcomings in SIRFLOX Design May Have Skewed PFS FindingsMay 3rd 2016
Navesh K. Sharma, DO, PhD, discusses the addition of Yttrium-90 resin microspheres to standard frontline FOLFOX-based chemotherapy with or without bevacizumab in patients with liver metastatic colorectal cancer.
Novel BTK, PI3K Inhibitors on Horizon for Relapsed CLLApril 30th 2016
With nearly a dozen new PI3K and BTK inhibitors currently in development for patients with relapsed chronic lymphocytic leukemia it is challenging to know which therapies are truly "next-generation" agents and which are "me too" products.